Figure 1.

(A) Top: Response types to therapy are shown for the overall population and several subgroups with specific risk factors. No significant differences were seen between different risk groups ( Table 1 ). Overall, 4 had CR (16%), 4 Cri (16%), and 5 MLFS (20%), for an ORR 52%. (B) Middle: Kaplan-Meier survival estimates are shown. A median follow-up of 14.6 months was seen (calculated by reverse-Kaplan-Meier). Median Overall Survival (OS) for the whole population was 5.5 (95% Cl, 2.9-21.6) months. Median OS for patients achieving cCR was 21.6 (95% Cl, 15.2-Not Reached) months, which was significantly longer than for those achieving MLFS at 4.4 (95% Cl, 2.4-6.6) months or no response at 3.0 (95% Cl, 0.8-5.8) months (Log-rank Chi² 11.62, p<0.009). One-year estimated OS was 38% for the entire population (95% Cl, 18.4% - 57.5%). (C) Bottom: Median OS for patients who were HMA-naïve is compared to those with prior HMA use. The HMA-naïve group had a median OS of 21.6 (95% Cl, 1.3-Not Reached) months compared to 4.3 (95% Cl, 1.3-6.6) months for those with prior exposure either for MDS treatment (n=2) or prior AML treatment (n=10) (HR=0.40, 95% Cl=0.15 to 1.07.)